Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial

•A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus g...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2017-10, Vol.35 (43), p.5897-5904
Hauptverfasser: Mo, Zhaojun, Mo, Yi, Li, Mingqiang, Tao, Junhui, Yang, Xu, Kong, Jilian, Wei, Dingkai, Fu, Botao, Liao, Xueyan, Chu, Jianli, Qiu, Yuanzheng, Hille, Darcy A., Nelson, Micki, Kaplan, Susan S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 5904
container_issue 43
container_start_page 5897
container_title Vaccine
container_volume 35
creator Mo, Zhaojun
Mo, Yi
Li, Mingqiang
Tao, Junhui
Yang, Xu
Kong, Jilian
Wei, Dingkai
Fu, Botao
Liao, Xueyan
Chu, Jianli
Qiu, Yuanzheng
Hille, Darcy A.
Nelson, Micki
Kaplan, Susan S.
description •A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus gastroenteritis caused by any serotype was 78.9%.•RV5 was efficacious and generally well-tolerated in Chinese infants. A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE). 4040 participants aged 6–12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385). VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related. In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.
doi_str_mv 10.1016/j.vaccine.2017.08.081
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1942678514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X17311817</els_id><sourcerecordid>1942678514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-5224a1f65e01787d340b7f41055691a6d0ec1f9342a075a4a0a8abde7f5d33a63</originalsourceid><addsrcrecordid>eNqFkc-KFDEQxoMo7rj6CErAywr2mHQ6_Wcvsgy7KiwIouItVCcVJkO6MybdDeMr-ZKbYUYPXoSCIpVf1Vd8RchLztac8frdbr2A1m7Edcl4s2ZtDv6IrHjbiKKUvH1MVqysq6Li7McFeZbSjjEmBe-ekouy7YSsGrYiv2-tdRr0gcJoaAKL04EGS4HucZxgAZ8T9W5Bup0HGIs-LFmURoSUQpwg_8aQQRfnRM8r0asv3-Ub6ka6RfDT9kA321xOmEs2d6RrekNjFgyD-4XmLTVh7j0WvXdjfu09aOxDocM4xeA9GjpFB_45eWLBJ3xxzpfk293t183H4v7zh0-bm_tCi05MhSzLCritJWZj2saIivWNzTZIWXccasNQc9uJqgTWSKiAQQu9wcZKIwTU4pJcnebuY_g5Y5rU4JJG72HEMCfFu6qsm1byKqOv_0F3YY5j3u5ICZbJimdKnigdQ0oRrdpHN0A8KM7U8Zpqp87WqeM1FWtzHPtenafP_YDmb9ef82Xg_QnAbMfiMKqkHY4ajYuoJ2WC-4_EAwfEtO4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1943094241</pqid></control><display><type>article</type><title>Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Mo, Zhaojun ; Mo, Yi ; Li, Mingqiang ; Tao, Junhui ; Yang, Xu ; Kong, Jilian ; Wei, Dingkai ; Fu, Botao ; Liao, Xueyan ; Chu, Jianli ; Qiu, Yuanzheng ; Hille, Darcy A. ; Nelson, Micki ; Kaplan, Susan S.</creator><creatorcontrib>Mo, Zhaojun ; Mo, Yi ; Li, Mingqiang ; Tao, Junhui ; Yang, Xu ; Kong, Jilian ; Wei, Dingkai ; Fu, Botao ; Liao, Xueyan ; Chu, Jianli ; Qiu, Yuanzheng ; Hille, Darcy A. ; Nelson, Micki ; Kaplan, Susan S.</creatorcontrib><description>•A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus gastroenteritis caused by any serotype was 78.9%.•RV5 was efficacious and generally well-tolerated in Chinese infants. A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE). 4040 participants aged 6–12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385). VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related. In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2017.08.081</identifier><identifier>PMID: 28935470</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Antigens ; Diarrhea ; Disease control ; Disease prevention ; Double-blind studies ; Effectiveness ; Efficacy ; Gastroenteritis ; Guardians ; Hospitalization ; Immunization ; Infants ; Intussusception ; Pediatrics ; Randomization ; Rotavirus ; Rotavirus gastroenteritis ; Rotavirus vaccine ; Safety ; Serotypes ; Surveillance ; Vaccination ; Vaccine efficacy ; Vaccines ; Viruses</subject><ispartof>Vaccine, 2017-10, Vol.35 (43), p.5897-5904</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Oct 13, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-5224a1f65e01787d340b7f41055691a6d0ec1f9342a075a4a0a8abde7f5d33a63</citedby><cites>FETCH-LOGICAL-c393t-5224a1f65e01787d340b7f41055691a6d0ec1f9342a075a4a0a8abde7f5d33a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1943094241?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28935470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mo, Zhaojun</creatorcontrib><creatorcontrib>Mo, Yi</creatorcontrib><creatorcontrib>Li, Mingqiang</creatorcontrib><creatorcontrib>Tao, Junhui</creatorcontrib><creatorcontrib>Yang, Xu</creatorcontrib><creatorcontrib>Kong, Jilian</creatorcontrib><creatorcontrib>Wei, Dingkai</creatorcontrib><creatorcontrib>Fu, Botao</creatorcontrib><creatorcontrib>Liao, Xueyan</creatorcontrib><creatorcontrib>Chu, Jianli</creatorcontrib><creatorcontrib>Qiu, Yuanzheng</creatorcontrib><creatorcontrib>Hille, Darcy A.</creatorcontrib><creatorcontrib>Nelson, Micki</creatorcontrib><creatorcontrib>Kaplan, Susan S.</creatorcontrib><title>Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus gastroenteritis caused by any serotype was 78.9%.•RV5 was efficacious and generally well-tolerated in Chinese infants. A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE). 4040 participants aged 6–12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385). VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related. In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.</description><subject>Age</subject><subject>Antigens</subject><subject>Diarrhea</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Double-blind studies</subject><subject>Effectiveness</subject><subject>Efficacy</subject><subject>Gastroenteritis</subject><subject>Guardians</subject><subject>Hospitalization</subject><subject>Immunization</subject><subject>Infants</subject><subject>Intussusception</subject><subject>Pediatrics</subject><subject>Randomization</subject><subject>Rotavirus</subject><subject>Rotavirus gastroenteritis</subject><subject>Rotavirus vaccine</subject><subject>Safety</subject><subject>Serotypes</subject><subject>Surveillance</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc-KFDEQxoMo7rj6CErAywr2mHQ6_Wcvsgy7KiwIouItVCcVJkO6MybdDeMr-ZKbYUYPXoSCIpVf1Vd8RchLztac8frdbr2A1m7Edcl4s2ZtDv6IrHjbiKKUvH1MVqysq6Li7McFeZbSjjEmBe-ekouy7YSsGrYiv2-tdRr0gcJoaAKL04EGS4HucZxgAZ8T9W5Bup0HGIs-LFmURoSUQpwg_8aQQRfnRM8r0asv3-Ub6ka6RfDT9kA321xOmEs2d6RrekNjFgyD-4XmLTVh7j0WvXdjfu09aOxDocM4xeA9GjpFB_45eWLBJ3xxzpfk293t183H4v7zh0-bm_tCi05MhSzLCritJWZj2saIivWNzTZIWXccasNQc9uJqgTWSKiAQQu9wcZKIwTU4pJcnebuY_g5Y5rU4JJG72HEMCfFu6qsm1byKqOv_0F3YY5j3u5ICZbJimdKnigdQ0oRrdpHN0A8KM7U8Zpqp87WqeM1FWtzHPtenafP_YDmb9ef82Xg_QnAbMfiMKqkHY4ajYuoJ2WC-4_EAwfEtO4</recordid><startdate>20171013</startdate><enddate>20171013</enddate><creator>Mo, Zhaojun</creator><creator>Mo, Yi</creator><creator>Li, Mingqiang</creator><creator>Tao, Junhui</creator><creator>Yang, Xu</creator><creator>Kong, Jilian</creator><creator>Wei, Dingkai</creator><creator>Fu, Botao</creator><creator>Liao, Xueyan</creator><creator>Chu, Jianli</creator><creator>Qiu, Yuanzheng</creator><creator>Hille, Darcy A.</creator><creator>Nelson, Micki</creator><creator>Kaplan, Susan S.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20171013</creationdate><title>Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial</title><author>Mo, Zhaojun ; Mo, Yi ; Li, Mingqiang ; Tao, Junhui ; Yang, Xu ; Kong, Jilian ; Wei, Dingkai ; Fu, Botao ; Liao, Xueyan ; Chu, Jianli ; Qiu, Yuanzheng ; Hille, Darcy A. ; Nelson, Micki ; Kaplan, Susan S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-5224a1f65e01787d340b7f41055691a6d0ec1f9342a075a4a0a8abde7f5d33a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Antigens</topic><topic>Diarrhea</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Double-blind studies</topic><topic>Effectiveness</topic><topic>Efficacy</topic><topic>Gastroenteritis</topic><topic>Guardians</topic><topic>Hospitalization</topic><topic>Immunization</topic><topic>Infants</topic><topic>Intussusception</topic><topic>Pediatrics</topic><topic>Randomization</topic><topic>Rotavirus</topic><topic>Rotavirus gastroenteritis</topic><topic>Rotavirus vaccine</topic><topic>Safety</topic><topic>Serotypes</topic><topic>Surveillance</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mo, Zhaojun</creatorcontrib><creatorcontrib>Mo, Yi</creatorcontrib><creatorcontrib>Li, Mingqiang</creatorcontrib><creatorcontrib>Tao, Junhui</creatorcontrib><creatorcontrib>Yang, Xu</creatorcontrib><creatorcontrib>Kong, Jilian</creatorcontrib><creatorcontrib>Wei, Dingkai</creatorcontrib><creatorcontrib>Fu, Botao</creatorcontrib><creatorcontrib>Liao, Xueyan</creatorcontrib><creatorcontrib>Chu, Jianli</creatorcontrib><creatorcontrib>Qiu, Yuanzheng</creatorcontrib><creatorcontrib>Hille, Darcy A.</creatorcontrib><creatorcontrib>Nelson, Micki</creatorcontrib><creatorcontrib>Kaplan, Susan S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mo, Zhaojun</au><au>Mo, Yi</au><au>Li, Mingqiang</au><au>Tao, Junhui</au><au>Yang, Xu</au><au>Kong, Jilian</au><au>Wei, Dingkai</au><au>Fu, Botao</au><au>Liao, Xueyan</au><au>Chu, Jianli</au><au>Qiu, Yuanzheng</au><au>Hille, Darcy A.</au><au>Nelson, Micki</au><au>Kaplan, Susan S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2017-10-13</date><risdate>2017</risdate><volume>35</volume><issue>43</issue><spage>5897</spage><epage>5904</epage><pages>5897-5904</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus gastroenteritis caused by any serotype was 78.9%.•RV5 was efficacious and generally well-tolerated in Chinese infants. A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE). 4040 participants aged 6–12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385). VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related. In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>28935470</pmid><doi>10.1016/j.vaccine.2017.08.081</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2017-10, Vol.35 (43), p.5897-5904
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_1942678514
source Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland
subjects Age
Antigens
Diarrhea
Disease control
Disease prevention
Double-blind studies
Effectiveness
Efficacy
Gastroenteritis
Guardians
Hospitalization
Immunization
Infants
Intussusception
Pediatrics
Randomization
Rotavirus
Rotavirus gastroenteritis
Rotavirus vaccine
Safety
Serotypes
Surveillance
Vaccination
Vaccine efficacy
Vaccines
Viruses
title Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A59%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20a%20pentavalent%20live%20human-bovine%20reassortant%20rotavirus%20vaccine%20(RV5)%20in%20healthy%20Chinese%20infants:%20A%20randomized,%20double-blind,%20placebo-controlled%20trial&rft.jtitle=Vaccine&rft.au=Mo,%20Zhaojun&rft.date=2017-10-13&rft.volume=35&rft.issue=43&rft.spage=5897&rft.epage=5904&rft.pages=5897-5904&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2017.08.081&rft_dat=%3Cproquest_cross%3E1942678514%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1943094241&rft_id=info:pmid/28935470&rft_els_id=S0264410X17311817&rfr_iscdi=true